新型非甾体抗炎药依托昔布  

Etoricoxib: a new non-steroid anti-inflammatory drug

作　　者：韩健[1] 赵志刚[1] 

机构地区：[1]首都医科大学附属北京天坛医院药剂科,北京100050

出　　处：《中国新药杂志》2009年第9期771-772,777,共3页Chinese Journal of New Drugs

摘　　要：新型选择性COX-2抑制剂依托昔布,适用于骨关节炎和类风湿关节炎症状缓解、急性痛风治疗、慢性肌肉骨骼痛的缓解、牙科手术相关性急性疼痛缓解和原发性痛经的治疗。文中对其药效学、药动学、临床评价、不良反应、药物相互作用等做一评述。Etoricoxib, a new non-steroid anti-inflammatory drug （NSAID） , is a selective COX-2 inhibitor. It can be used for the treatment of osteoarthritis, rheumatoid arthritis, acute gout, chronic musculoskeletal pain, acute dental surgery pain and primary dysmenorrheal pain. In this paper, pharmaeodynamics, pharmacokinetics, clinical assessments, adverse reactions, and drug interactions of etoricoxib were reviewed.

关 键 词：依托昔布 非甾体抗炎药 药理作用 临床评价 

分 类 号：R971.1[医药卫生—药品]